Alex Jaimes

Alex Jaimes

Auto-generated profile, based on publicly available information

Alex Jaimes

Headache Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2025 in Cephalalgia
Verified
Journal Article
Open access
AJAlex Jaimes
Alex Jaimes
JRJaime Rodríguez-Vico
Jaime Rodríguez-Vico
OPOlga Pajares
Olga Pajares
ICIgnacio Eguilior Caffarena
Ignacio Eguilior Caffarena
AHAnna Lena Nystrom Hernández
Anna Lena Nystrom Hernández
Jesus Porta EtessamJesus Porta Etessam
Jesus Porta Etessam
Background: A subset of individuals with episodic migraine (EM) and chronic migraine (CM) does not respond to anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs), even after switching agents. Although atogepant is effective in EM and CM, its role in individuals unresponsive to anti-CGRP mAbs remains to be elucidated. We hypothesize that atogepant may be a viable preventive option in these cases. Methods: We conducted a retrospective cohort study in EM and CM individuals who discontinued anti-CGRP mAbs due to lack or loss of efficacy and were subsequently treated with atogepant. The primary endpoint was the ≥50% response rate in monthly headache days (MHDs). Secondary outcomes included ≥30% and ≥75% response rates in MHDs, response rates in monthly moderate-to-severe headache days (MSHDs), and changes in MHDs, MSHDs, acute medication days (AMDs) and Headache Impact Test (HIT-6). Patient Global Impression (PGI) scores and adverse events (AEs) were recorded. Results: Of 213 screened records, 44 participants met inclusion criteria; 39 (88.6%) were female and 39 (88.6%) had CM. Prior use of anti-CGRP mAbs included erenumab in 11.4% of participants, galcanezumab in 52.3% and fremanezumab in 86.3%. After three months, 18.2% achieved a ≥50% reduction in MHDs; ≥30% and ≥75% response rates were 25.0% and 6.8% respectively. For MSHDs, ≥30%, ≥50% and ≥75% response rates were 47.6%, 33.3% and 19.0%, respectively. Median MHDs decreased from 24.5 (interquartile range (IQR) = 16.0–30.0; range 9.0–31.0) to 21.5 (IQR = 10.0–30.0; range 3.0–31.0; p = 0.011), and median MSHDs from 15.0 (IQR = 10.0–25.5; range 5.0–30.0) to 12.0 (IQR = 5.9–19.0; range 0.0–30.0; p = 0.001). AMDs and HIT-6 scores also showed significant reductions. According to the PGI scale, 59.1% of individuals reported some degree of improvement. AEs occurred in 50.0% of participants, most commonly constipation (31.8%). Five (11.4%) participants discontinued treatment due to side effects. Conclusions: After three months of treatment, atogepant led to a clinically meaningful improvement in a subset of participants. It may be a valuable preventive option for individuals unresponsive to anti-CGRP mAbs and warrants further investigation in prospective studies.

27 December 2024 in Headache: The Journal of Head and Face Pain
Verified
Journal Article
Open access
AJAlex Jaimes
Alex Jaimes
AGAndrea Gómez
Andrea Gómez
OPOlga Pajares
Olga Pajares
JRJaime Rodríguez‐Vico
Jaime Rodríguez‐Vico
Objective: To evaluate the effectiveness of first switching between monoclonal antibodies (mAbs) targeting calcitonin gene–related peptide (CGRP) or its receptor in the treatment of migraine. Background: Although mAbs targeting CGRP or its receptor have emerged as a leading treatment for migraine prevention, a proportion of patients do not respond. While switching between these antibodies is a common clinical practice in such cases, the effectiveness remains a subject of study. Methods: We conducted a retrospective cohort study at a tertiary headache center, analyzing data from clinical records of patients treated with anti‐CGRP mAbs from January 2020 to March 2024. Baseline was defined as the monthly headache days (MHDs) in the 3 months prior to the start of the second mAb. The primary endpoint was the change in MHDs at month 3 and month 6 following the switch. Additionally, we evaluated response rates in both periods. Subgroup analyses were conducted based on changes in mechanism of action. Finally, we assessed the influence of the number of doses of the first mAb and the inter‐treatment interval. Results: Out of 1244 initially identified patients, 185 were included in the month‐3 analysis and 123 in the month‐6 evaluation. The median MHDs decreased from 27.0 (interquartile range [IQR] 16.1, 30.0; range 5.0, 30.7) at baseline to 21.0 (IQR 10.0, 30.0; range 0.0, 30.0; p < 0.001) at month 3, and to 20.0 (IQR 10.0, 30.0; range 0.0, 31.0; p < 0.001) at month 6. Subgroup analyses revealed no significant differences in MHDs between maintaining the same target or changing it (baseline: 28.0 [IQR 16.2, 30.0; range 5.0, 31.0] vs. 27.0 [IQR 6.0, 31.0; range 6.0, 31.0]; month 3: 23.0 [IQR 10.0, 30.0; range 0.0, 31.0] vs. 19.0 [IQR 11.0, 30.0; range 1.0, 31.0], p = 0.144; month 6: 24.0 [IQR 11.0, 30.0; range 0.0, 31.0] vs. 17.0 [IQR 10.0, 30.0; range 3.0, 31.0], p = 0.170). There was no association between a ≥50% reduction in MHDs and the number of previous doses of the first mAb (odds ratio [OR] 1.0; 95% confidence interval [CI] 1.0, 1.1; p = 0.189) or the inter‐treatment interval (OR 1.0; 95% CI 0.9, 1.1; p = 0.914). Conclusion: Switching between anti‐CGRP mAbs resulted in a reduction in MHDs, with no significant differences based on the mechanism of action. Factors such as the number of doses of the first mAb and the inter‐treatment interval did not appear to predict a ≥50% reduction in MHDs at month 3. Our findings support the viability of switching as an effective treatment option for patients with migraine who do not respond to initial mAb therapy.

3 June 2025 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
MGMaría Clara García-Castillo
María Clara García-Castillo
AMAlvaro Sierra Mencia
Alvaro Sierra Mencia
ECEdoardo Caronna
Edoardo Caronna
DTDaniel Toledo-Alfocea
Daniel Toledo-Alfocea
AJAlex Jaimes
Alex Jaimes
AGAlicia Gonzalez-Martinez
Alicia Gonzalez-Martinez
Background: Preclinical evidence supports the immunoregulatory role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology. The increasing use of anti-CGRP therapies in patients with migraine and other comorbidities raises the question whether the potential use of anti-CGRP monoclonal antibodies (CGRP-mAbs) therapies in combination with other immunological therapies is effective and safe. Methods: This multicenter study included patients with migraine receiving CGRP-mAbs combined with immunosuppressive and immunomodulatory treatments. Clinical and demographic data, treatment history, laboratory markers and treatment-emergent adverse events (TEAEs) were analyzed. Effectiveness outcomes included the change in monthly migraine days (MMD) and monthly headache days (MHD) at 3, 6, 9 and 12 months, alongside the > 50% response rate. Moreover, autoimmune disease progression was also evaluated. We explored differences between patients with and without autoimmune disease activation. Results: Among 89 patients, there were 80 (90%) females with a mean age of 50 years (SD: 11), who had a high prevalence of psychiatric comorbidities (anxiety 44%, depression 49%) and medication overuse (68%). Patients receiving immunological treatments experienced significant reductions in MMD and MHD, with MMD decreasing from 16 (SD: 7) at baseline to 9 (SD: 8) at 6 months, and MHD dropping from 23 (SD: 8) to 17 (SD: 11). A 50% response in MMD was achieved by 46% at 6 months. TEAEs were reported in 28%, most commonly constipation (16%) and dizziness (9%). Conclusions: CGRP-mAbs therapies combined with immunological treatments appear effective and safe in patients with autoimmune diseases. Larger prospective studies are necessary to confirm these findings and optimize management strategies.

24 February 2026 in Neurology
Verified
Journal Article
Closed access
ECEdoardo Caronna
Edoardo Caronna
RMRut Mas-De-Les-Valls
Rut Mas-De-Les-Valls
GEGabriella Egeo
Gabriella Egeo
MVManuel Millán Vázquez
Manuel Millán Vázquez
CNCandela Nieves-Castellanos
Candela Nieves-Castellanos
PPPatricia Pozo-Rosich
Patricia Pozo-Rosich
The aim of this study was to describe the long-term effectiveness and treatment persistence of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (MAbs) in migraine and to identify baseline factors associated with 2-year treatment continuation. A prospective observational multicenter registry-based study of anti-CGRP MAbs was conducted. We analyzed changes in monthly headache days (MHDs) at 24 months (M24) compared with baseline in those who reached M24 (ON-group). We analyzed patterns of response at 4 time points (6, 12, 18, and 24 months). We defined sustained response (SR) as a ≥50% reduction in MHDs at ≥3 of 4 time points. We compared baseline characteristics of the ON-group with those of the discontinuation group because of lack of effectiveness (OFF-group). A total of 1,340 individuals reached M24 (ON-group: median age 48.0 [41.0-55.0] years; 81.7% female). The median MHD at baseline was 20.0 (13.0-28.0) days. At M24, 60.4% of patients demonstrated ≥50% reduction in MHDs (809/1,340). The proportion of participants achieving SR at M24 was 53.8% (142/264). When compared with the ON-group (n = 1,340), the OFF-group (n = 1,057) showed statistically significant higher baseline MHDs (ON: 20.0 [13.0-28.0] vs OFF: 25.0 [16.0-28.0]) and a greater proportion of patients with aura (ON: 16.2% vs OFF: 22.9%), depression (ON: 22.8% vs OFF: 37.9%), and obesity (ON: 7.2% vs OFF: 19.1%) (p < 0.001). Sustained reductions in MHDs to anti-CGRP treatment at 2 years was observed. Delayed treatment onset, migraine with aura, depression, and obesity may negatively affect treatment persistence. This study provides Class IV evidence that, in patients with migraine, treatment with anti-CGRP MAbs is associated with sustained reductions in MHDs over a 24-month period.

24 December 2022 in Pain Practice
Verified
Journal Article
Closed access
AJAlex Jaimes
Alex Jaimes
AGAndrea Gómez
Andrea Gómez
OPOlga Pajares
Olga Pajares
JRJaime Rodríguez‐Vico
Jaime Rodríguez‐Vico

23 June 2026 in Neurology
Verified
Journal Article
Closed access
PDF file
ECEdoardo Caronna
Edoardo Caronna
RMRut Mas-De-Les-Valls
Rut Mas-De-Les-Valls
GEGabriella Egeo
Gabriella Egeo
MVManuel Millán Vázquez
Manuel Millán Vázquez
CNCandela Nieves-Castellanos
Candela Nieves-Castellanos
PPPatricia Pozo-Rosich
Patricia Pozo-Rosich